Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Jul 16, 2022; 10(20): 6811-6824
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6811
Table 2 Other factors influenced by hangebyakujutsutemmato treatment in Persistent postural-perceptual dizziness patients


Non-HBT (n = 14)
HBT (n = 24)
P value1
DHIBaseline49.6 ± 24.650.8 ± 20.10.44
1 mo45.7 ± 25.843.0 ± 3.00.37
2 mo42.7 ± 25.038.8 ± 24.30.32
SubcategoryDHI-PBaseline11.9 ± 7.614.9 ± 6.20.11
1 mo11.4 ± 7.111.8 ± 7.10.43
2 mo11.0 ± 6.811.3 ± 6.90.46
DHI-EBaseline19.6 ± 8.916.7 ± 8.60.17
1 mo17.3 ± 9.714.7 ± 9.00.21
2 mo15.3 ± 9.512.7 ± 9.70.21
DHI-FBaseline18.1 ± 11.319.3 ± 8.80.38
1 mo17.0 ± 11.816.5 ± 10.10.45
2 mo16.4 ± 10.614.8 ± 9.70.32
HADSBaseline15.8 ± 8.315.0 ± 7.30.39
1 mo15.6 ± 7.813.8 ± 8.60.25
2 mo15.6 ± 8.613.0 ± 9.50.19
SubcategoryHADS-ABaseline8.9 ± 5.09.0 ± 4.00.49
1 mo8.1 ± 4.47.8 ± 4.40.42
2 mo7.9 ± 5.07.7 ± 4.80.45
HADS-DBaseline6.9 ± 4.16.1 ± 4.30.29
1 mo7.6 ± 4.56.0 ± 4.70.16
2 mo7.7 ± 4.85.3 ± 5.30.08
OD scoreBaseline6.1 ± 2.27.8 ± 5.40.08
1 mo5.9 ± 2.65.9 ± 2.90.48
2 mo5.6 ± 3.05.6 ± 2.60.48
Graybiel’s motion sickness scoreBaseline26.0 ± 11.025.8 ± 11.20.47
1 mo19.3 ± 7.619.9 ± 8.40.41
2 mo23.3 ± 12.418.1 ± 6.90.08
PSQIBaseline8.9 ± 3.510.0 ± 3.40.19
1 mo8.6 ± 3.09.0 ± 4.60.37
2 mo8.5 ± 3.19.6 ± 4.10.19